Tetanus remains a serious problem in public health, particularly in developing countries, despite efficient prevention programs. A retrospective study was conducted at an infectious diseases intensive care unit during 1998-2003 involving patients admitted with grade III tetanus. The aim of the study was to evaluate the efficacy and safety of intrathecal baclofen for the treatment of tetanus. Lumbar puncture was performed, and a subarachnoid catheter was inserted for drug administration. An intrathecal bolus of baclofen was followed by a continuous infusion of 20 mg/h, until a maximum daily dose of 2 mg was provided. Twenty-two patients were treated overall. Control of the symptoms was achieved in all patients but one. Seven patients had colonization of the catheter, and 1 patient developed meningitis. All patients except one recovered. In our study, this means of treatment was efficacious and well tolerated.
Tetanus is an acute, often fatal disease caused by an exotoxin produced by Clostridium tetani. Although the disease can be effectively prevented by immunization with tetanus toxoid, it still remains a serious problem in public health, particularly in developing countries. At the present time, tetanus occurs predominantly in these regions, where it affects persons of all ages, but it is also observed in industrialized countries, usually in adults aged 160 years and in unimmunized or inadequately immunized persons. It has also recently been described in injection drug users [1] .
Tetanus is an uncommon disease in Portugal, although Portugal has the highest prevalence of tetanus among the countries in the European Union. In 1999, the prevalence of tetanus in Portugal was 0.25 cases per 100,000 inhabitants [2] .
The diagnosis of tetanus is based on clinical grounds and is characterized by trismus, difficulty swallowing, dysphagia, muscle rigidity, and spasms, usually in pa-tients with a previous wound [3, 4] . Therapy is directed at providing supportive care, neutralizing circulating toxin, removing the source of tetanospasmin, and managing potential complications. Attention must be given to the site of entry, and wound debridement, with removal of necrotic tissue and foreign material, must be done whenever necessary. Treatment with tetanus immunoglobulin (250-500 IU given im) and an antibiotic, such as metronidazole (500 mg q.i.d. po), penicillin (10-15 MU q.d. iv), or tetracycline (500 mg q.i.d. po) for 7-10 days, is recommended. Tetanus toxoid vaccine should be given at the moment of diagnosis and 4-6 weeks and 1 year later, because tetanus does not confer immunity [5] . Symptomatic treatment with benzodiazepines and muscle relaxants and other supportive measures must also be administered. Patients with more severe forms of the disease must be admitted to an intensive care unit, where sedative agents can be administered and neuromuscular blockade, tracheotomy, and mechanical ventilation can be provided [4, 5] . Tracheotomy is usually done when patients have difficulty swallowing. Sedation of these patients with diazepam has been performed for years, but more recently, some other therapeutic options have been tried to improve the outcome of more severe forms of the disease.
g-Aminobutyric acid (GABA) receptors are included in the group of ionic activated channels, as are the nicotinic receptor of acetilcolyne and the glycine receptor. The linking of GABA to the GABA A receptors promotes the opening of chloride channel receptors, which increases the permeability of cellular membrane to chloride, leading to cellular depolarization. Midazolam enhances GABA activation, increasing the frequency of chloride channel activation, whereas propofol prolongs the time of activation of these channels [6] . The administration of midazolam, a hydrosoluble benzodiazepine, in a continuous intravenous infusion allows more efficient sedation of patients than does diazepam in a bolus [7] . Propofol, which acts by enhancing activation of the GABA A receptors, is another option that, depending on the dose administered, may be used as a sedative or to control spasms and muscle rigidity [8] . When sedation with midazolam is not sufficient, the patient can be paralyzed with muscle-blocking agents. Analgesia with morphine or fentanyl is also used as needed.
Intrathecal baclofen is the most recent option for the treatment of tetanus. Baclofen is a GABA B receptor agonist that inhibits pre-synaptic acetylcholine release and synaptic medullar reflexes (i.e., lowers excitability of motor neurons), which results in an antispastic action. GABA B activation receptors do not alter cellular permeability to chloride, as do GABA A activation receptors; they instead act by lowering calcium permeability in primary afferents. Baclofen is currently used to treat spastic neurological diseases, but it is also an option for the treatment of muscular rigidity and paroxysms of tetanus. Because it does not cross the blood-brain barrier, and because high intrathecal concentrations must be achieved in tetanus patients, baclofen needs to be administered directly in the subarachnoid space. However, it does not interfere with the autonomic dysfunction observed in more severe forms of disease [9] [10] [11] .
Adverse effects include drowsiness, weakness, dizziness, nausea, confusion, and hypotension. Intrathecal baclofen must be used with caution in patients with liver disease, peptic ulcer, and diabetes mellitus and in elderly persons, among whom adverse effects may be more common. Abrupt withdrawal of therapy may exacerbate spasticity, so the dosage should be reduced gradually. Secondary effects are antagonized with flumazenil therapy [12] . The aim of the present study is to report our experience with intrathecal baclofen for the treatment of tetanus.
PATIENTS AND METHODS
Baclofen has been used to treat spastic neurological diseases, and, in recent years, some clinicians have also used it to treat muscular rigidity associated with tetanus. A retrospective study was conducted that involved patients with a diagnosis of tetanus who were admitted to an infectious diseases intensive care unit (ID-ICU) at Hospital S. João and School of Medicine (Porto, Portugal) during the period of 1998-2003. The study evaluated the efficacy and safety of baclofen administered by the intrathecal route. All patients with a diagnosis of grade III tetanus who were admitted to the ID-ICU were included in the study. A diagnosis of tetanus was considered for patients with a previous wound and muscle contractures (e.g., trismus, difficulty swallowing, dysphagia, muscle rigidity, and spasms) on the basis of Centers for Disease Control and Prevention criteria [4] . Severity of tetanus was classified as follows: grade I, rigidity of a single muscle group; grade II, rigidity of у2 muscle groups, without paroxysms; grade IIIA, generalized rigidity and paroxysms of skeletal muscles; and grade IIIB, severe manifestations, as listed above, with autonomic dysfunction [13] .
All patients underwent a lumbar puncture, and a tunneled catheter (BD Perisafe) was placed in the subarachnoid space and connected to a filter reservoir (figures 1 and 2). An initial bolus of intrathecal baclofen (40-200 mg) was followed by con- tinuous infusion that began at a dosage of 20 mg/h and was increased by 8 mg every 4 h, to abolish muscle rigidity and spasms or until a maximum daily dose of 2 mg was achieved. Baclofen was prepared in the pharmacy department in a syringe (40 mg/mL) for infusion. The severity of muscle rigidity and spasms was determined as noted at admission and after the intrathecal infusion of baclofen was started according to the Ashworth scale score [9] , as follows: 1, no increase in muscle tonus; 2, light increase in flexion and extension of muscle group; 3, increase in muscle tonus but movements possible; 4, passive movements difficult; and 5, rigidity without movements.
Routine CSF studies, including bacterial cultures, were done when the catheter was inserted, weekly thereafter or whenever fever appeared, and when the catheter was removed. All patients underwent continuous monitoring of blood pressure, electrocardiography, and oxygen saturation and received respiratory support, as needed. Creatine kinase values were determined every 24 h, and other blood studies were done as appropriate.
RESULTS
Twenty-two patients were admitted to the ID-ICU from January 1998 through March 2003. Demographic data and severity parameters are shown in tables 1 and 2. Patient ages ranged from 32 to 84 years ( , years), and 15 patients mean ‫ע‬ SD 64 ‫ע‬ 13 (68%) were women. All cases were classified as grade III.
All patients underwent surgical treatment and received antibiotic therapy with penicillin or tetracycline, because we have a good experience with these antibiotics. Tracheotomy was performed at hospital admission for all patients with grade III tetanus. Midazolam was administered in a continuous infusion (0.03-0.2 mg/kg q.d.) with additional intravenous boluses of 3 mg, as needed; propofol (1-4 mg/kg per h) was used for some patients as well. Analgesia with morphine or fentanyl was provided for all patients, as was prophylactic heparin, sucralfate, and enteric feeding. Curarization was done most frequently with vecuronium. An intrathecal baclofen infusion was administered to all patients with grade III tetanus who were admitted after 1998; it was given as soon as possible after admission. The 22 patients were treated with intrathecal baclofen р72 h after hospital admission (range, 1-3 days; mean ‫ע‬ SD, 22 ‫ע‬ 0.78 h). After the intrathecal catheter was inserted, baclofen was infused, as described above, at a maximum dosage of 80 mg per h. Higher doses were necessary for patients with tetanus associated with drug addiction (table 3). The doses of sedatives and muscle relaxants were gradually decreased, and administration of these agents was stopped as soon as possible.
After the baclofen infusion was started, 3 patients had spontaneous ventilation, 4 patients required mechanical ventilatory support for !5 days, and the other patients required ventilatory support for 12-55 days ( , ). Seven patients mean ‫ע‬ SD 18 ‫ע‬ 14.1 were treated at an emergency department or a medical center on the day of the injury and did not receive tetanus prophylaxis. Three of these patients had received wound treatment at their local medical center, 2 patients had lacerations of the legs, 1 patient had head trauma with an occipital abrasion after an aggression during a fight, and 1 patient had experienced multiple traumas and had been admitted to an orthopedic service.
Muscle rigidity was evaluated on the basis of the Ashworth scale score at admission to the ID-ICU and every day after treatment with baclofen was started (table 4). Hypotension (mean blood pressure, !60 mm Hg) was noted for 13 patients; it was particularly common among those who had received a higher initial dose of baclofen (i.e., 200 mg). For all affected patients, it was corrected with intravenous fluid therapy.
In 1 patient, displacement of the intrathecal catheter out of the subarachnoid space occurred 2 days after inserted. This patient required curarization and mechanical ventilatory support for 2 days to control the severe muscle rigidity. In another patient, who was addicted to drugs, intrathecal perfusion of baclofen to a maximum dosage of 3 mg/day had no effect in controlling the paroxysms and muscle rigidity. We do not know whether the severity of the paroxysms and muscle rigidity was associated with a larger inoculum, because the patient had multiple inflammatory lesions on his arms, or whether it was somehow related to drug addiction. For this patient, the baclofen infusion was stopped, and treatment with midazolam and vecuronium was prescribed.
Microbiologic studies were performed regularly during the baclofen infusion. The intrathecal catheter was connected to a filter reservoir that was never manipulated during the infusion time. In addition to weekly CSF cultures, when the catheter was removed after skin disinfection with iodopovidone (the skin was disinfected with 3 different gauze swabs), a CSF specimen was collected, and the last 5-cm on the tip of the catheter was inserted into a sterile microbiologic tube and sent for culture. One patient had secondary infection of the catheter that was complicated by Staphylococcus epidermidis meningitis. He was treated with vancomycin for 2 weeks and recovered without Other complications that occurred were nosocomial pneumonia (4 patients), infection of the central venous catheter (3 patients), both renal failure and lung athelectasis (2 patients), tracheomalacy (1 patient), and traumatic vesical hemorrhage (1 patient). All patients but 1 who were treated with baclofen survived. The patient who died had been admitted to the Trauma Department a week earlier after a vehicle accident. The patient had fractures of both legs and extensive necrosis of the feet with secondary infection and died 10 days after tetanus was diagnosed. At the emergency department, the patient was given a booster of the tetanus vaccine only.
DISCUSSION
Tetanus remains a clinical problem in developing countries, where intensive care facilities are limited and good support treatment is very difficult to obtain. Also, in some developed countries, the incidence of the disease still is high; in these regions elderly persons, immunocompromised patients, and injection drug users are the most frequently affected groups. Management of symptoms is difficult, particularly for patients with the more severe forms of the disease and autonomic dysfunction [14, 15] .
There are still some controversies about treatment of severe forms of tetanus. For controlling rigidity and spasms, no drug has been consistently effective, and a wide variety of drugs, such as benzodiazepines and propofol (single or in combination), have been used. Baclofen, linking in GABA B receptors, inhibits brainstem and spinal motor neurons, thus antagonizing the effect of tetanus toxin action in GABA receptors, which reduces motorneural excitability. For the majority of our pa- tients, baclofen treatment did not preclude the need for mechanical ventilation, but it has the advantage of avoiding longterm sedation, reducing the duration of and complications associated with respiratory support, and decreasing the duration of hospital stay.
Clinical effects are dose dependent, and the therapeutic range of intrathecal baclofen dose for severe tetanus is narrow and varies from patient to patient. Hypotension, hypotonia, respiratory arrest, coma, and arreflexia can occur after a small increase in the dosage of intrathecal baclofen.
There are several case reports of beneficial responses to 1-2 mg per day of intrathecal baclofen. Some clinicians have administered baclofen via repeated intrathecal injections because of the risk of secondary infection of the catheter [16] , and others have administered it via continuous infusion. In 1986, Muller et al. [17] reported 2 cases of tetanus that were successfully treated with an intrathecal bolus, with weaning from ventilatory support within 2 days. In 1992, Saissy et al. [18] described 10 patients from Senegal who were treated with repeated intrathecal bolus injections of baclofen. Five of these patients required curarization and ventilatory support, and only 1 of these patients was cured. Of the other 5 patients who were treated exclusively with baclofen, 4 were cured. In 1997, Dressnandt et al. [12] described 4 cases of tetanus that were successfully treated with a continuous perfusion of intrathecal baclofen, but all affected patients had previously been administered benzodiazepines or muscle relaxants. In 1999, Engrand et al. [19] reported a study of 14 patients who were treated with intrathecal baclofen in bolus injections followed by perfusion. Good spasticity control was obtained, but the mortality and morbidity were significant (mortality rate, 35.7%), and 3 cases of meningitis occurred.
In our patients, the intrathecal catheter was placed soon after hospital admission. The bolus doses and perfusion syringes of baclofen were prepared in aseptic conditions at the pharmacy department. All patients began receiving baclofen between the first and third day after admission, but when patients were admitted on the weekend, it was not possible to begin treatment early. Mechanical ventilatory support was provided 2-55 days after baclofen infusion. Three patients did not require mechanical ventilatory support.
In our study, as in others, we found that response to the same dosage of baclofen was very different from patient to patient. Because a standardized dosage is not possible, we varied the initial bolus by body weight. The most frequent side effects after the initial bolus were hypotension (mean arterial pressure, !60 mm Hg), which occurred in 13 patients but which was corrected with intravenous fluid therapy, and bradycardia, which was reversed by lowering the perfusion rate.
The risk of secondary infection of an indwelling intrathecal catheter and of meningitis is increased when an indwelling intrathecal catheter is present in the subarachnoid space, so CSF analysis was performed for all patients initially, at weekly intervals, whenever fever occurred, and when the catheter was removed [11, 16, 18, 19] . In our patients, the duration of perfusion ranged from 8 to 30 days ( , days). mean ‫ע‬ SD 18 ‫ע‬ 6 S. epidermidis meningitis occurred in 1 patient after 14 days of treatment; after catheter removal and treatment with vancomycin for 2 weeks, he was cured without sequelae. In 7 other patients, colonization of catheter tip was documented.
We found that intrathecal baclofen is a good option for control of tetanus spasticity, which has been reported by other authors [20] . In our experience, continuous perfusion is more effective than an intermittent infusion or bolus because it allows small adjustments to the dosage, which is an important feature for elderly recipients. In our cohort, the mortality rate was low (5%), and it was one of the lowest when compared with other studies of patients treated with baclofen. From 1988 through 1997, at our ID-ICU, we treated 118 patients with grade III tetanus, 97 of whom required ventilatory support, with a mortality rate of 18.6%. [21] . Mortality associated with tetanus varies, depending on the patient's age and immune status and on the facilities for treatment. The mortality rate for tetanus can reach 50% in developing countries, with respiratory complications constituting the major cause of mortality [4, 5, 15] . Baclofen treatment seems to be more comfortable for patients than other treatments, because patients have less muscle rigidity and less pain, and because it permits a more alert state, making communication easier.
It should be remembered that severe tetanus requires prolonged intensive care, with the risk of related complications, morbidity, and mortality, as well as high costs. If secondary prophylaxis had been correctly administered to all of our patients, the disease could have been avoided.
Adults, elderly individuals, pregnant women, injection drug abusers, and immunocompromised persons should be vaccinated. Particular attention should be paid to nonimmunized persons with injuries, for whom secondary prophylaxis with tetanus immunoglobulin and tetanus vaccine should be performed [22] [23] [24] .
Tetanus disease does not result in immunity to tetanus, so active immunization should continue to be administered after the disease is cured. It is important that active immunization programs be performed by public health departments, to prevent a disease with high mortality and morbidity.
